艾迪藥業(688488.SH):與藥石科技終止項目合作開發框架合同
格隆匯4月8日丨艾迪藥業(688488.SH)公佈,公司及其全資子公司南京艾迪醫藥科技有限公司與南京藥石科技股份有限公司(簡稱“藥石科技”或“乙方”)經友好協商,於2022年8月簽訂了《項目合作開發框架合同》(簡稱“原框架合同”),雙方擬在抗新冠肺炎病毒3CL蛋白酶抑制劑創新靶點和創新化合物領域共同開發新藥。由於本項目的客觀環境及市場前景發生重大變化,經友好協商,雙方一致同意提前終止原框架合同及附屬服務合同,並簽訂終止協議。簽訂終止協議是綜合考慮了公司整體經營發展規劃和客觀環境變化而做出的謹慎決策,有利於公司集中資源於抗HIV及人源蛋白優勢領域,符合公司的整體發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.